Scientific publications
At Day One, we use the power of leading-edge science to improve patient outcomes.
We believe timely and transparent dissemination of data from our clinical trials and other studies is essential to inform clinical decision making and to advance scientific understanding. Our comprehensive list of publications is below.
November 2022
June 2022
November 2021
Activity of pan-RAF inhibitor DAY101 in a pediatric patient with a recurrent spindle cell sarcoma harboring a novel SNX8-BRAF gene fusion
2021 Connective Tissue Oncology Society Annual Meeting
October 2021
FIRELIGHT: DAY101-102a, a phase 2 subprotocol of DAY101 monotherapy for patients with recurrent, progressive, or refractory solid tumors with an activating BRAF gene fusion
18th International Congress of the Society for Melanoma Research
October 2021
Prolonged complete response to the pan-RAF inhibitor DAY101 in a patient with an NRAS-mutated acral lentiginous melanoma
18th International Congress of the Society for Melanoma Research
April 2021
Pan-RAF inhibitor DAY101 exhibits preclinical activity in preclinical tumor models harboring BRAF alterations beyond BRAF V600E mutation
Pan-RAF inhibitor DAY101 exhibits preclinical activity in preclinical tumor models harboring BRAF alterations beyond BRAF V600E mutation. Abstract 1481. Presented at the American Association for Cancer Research Annual Meeting, April 10-15, 2021.